Multiple Sclerosis: KOL Insight

An incisive report and dynamic analyst briefing service delivering insight from the most influential Multiple Sclerosis (MS) Key Opinion Leaders to map the current treatment landscape and analyse future trends.

Multiple Sclerosis : The oral era begins

The multiple sclerosis treatment landscape has undergone dramatic changes over the past year. Biogen’s Tecfidera (dimethyl fumarate) has revolutionised multiple sclerosis treatment in the US, cannibalising significant market share from older therapies. With New Active Substance status granted in Europe, Tecfidera’s launch is expected to be replicated in this region. Genzyme have taken advantage of this delay with Lemtrada’s (alemtuzumab) and Aubagio’s (teriflunomide) EU approval. The arrival of these drugs is expected to change how multiple sclerosis is treated and be a catalyst for unprecedented market growth.

Driven by in-depth interviews with the world’s leading multiple sclerosis KOLs, Therapy Trends: Multiple Sclerosis uncovers how the current treatment landscape will be impacted by significant future events, with particular focus on pipeline therapies and how these will modify the way MS is managed by neurologists in the future.

Drive your strategic decision-making with inside intelligence

Multiple Sclerosis : KOL Insight disseminates critical opinion and analysis to provide premier research.

  • We cut to the heart of market-changing events and eliminate superfluous background information so you can focus on developments of greatest strategic impact and reduce your reaction time
  • Our unique thought-leader selection matrix identifies the most influential KOLs in MS to deliver the perspectives vital in giving you a competitive edge, enabling informed decision-making and planning
  • Detailed analysis of marketed and pipeline drugs helps you understand the products that will shape the future MS market
  • KOL consensus on the future treatment algorithm offers a window into the future changes in medical evidence and clinical practice
  • Uncovering KOLs’ opinions on unmet needs enables you to identify potential commercial opportunities
  • Dynamic report updates evaluate the market impact of key events from KOL perspectives, allowing you to react to significant MS market developments within days of events occurring
Critical questions answered

Our MS KOLs are selected according to their level of engagement and influence within the pharmaceutical industry and their scientific standing. FirstWord’s unique KOL scoring system enables identification of KOLs with the greatest knowledge of how MS treatment will evolve and shape the future landscape.

  • What are the key unmet needs? There is a high risk, high reward opportunity in the development of a therapy with efficacy for progressive subtypes.
  • How will therapies will be positioned against each other in the future of MS treatment? Biogen’s new oral therapy Tecfidera is expected to usurp the current market leaders and become the first-line therapy of choice.
  • Where do neurologists position Lemtrada? Insight from 300 prescribers surveyed on positioning, prescription and pricing.
  • How will treatment developments play out in the near future? Biogen's activity in broadening its robust pipeline shows its resolve in maintaining its leading position in MS.
  • Is there potential for new players in the lucrative MS market? New entrants are set to capture significant share and cannibalise sales of the leading drugs.
  • How will the launch of biosimilars affect prescribing behaviour? Pricing will be a key determinant in positioning and uptake.
  • Will Teficdera’s European launch replicate the US success? A delayed launch in Europe appears to have stimulated demand for Tecfidera among neurologists and MS patients.
  • Will the new John Cunningham Virus test encourage earlier adoption of Tysabri? This offers the first example of personalised medicine; a trend that will aid uptake in future.
The deliverables

Therapy Trends: Multiple Sclerosis is delivered in two complimentary formats:

Therapy Trends Intelligence Report: a concise, focused, in-depth market intelligence research report that examines the range of current and late-stage pipeline drugs to determine future trends in the treatment and diagnosis of MS, and assess the commercial impact on the MS market landscape.

Therapy Trends Impact Assessments: dynamic analyst briefings evaluating the impact of events in the MS market over the next 12 months, delivered to you within days of a significant event happening

Who should buy this report?

This report will be of value to senior pharma directors and managers with responsibilities in the following areas:

  • Business Development
  • New Product Planning
  • Market Research
  • Strategic brand planning
  • Forecasting and marketing professionals
  • Medical Affairs
  • Clinical Trials
  • Relationship Management
  • Contents
  • Executive summary
  • Introduction
  • Methodology
  • Current Multiple sclerosis marketplace
    > Current treatment landscape
    > Multiple Sclerosis market definition
    > Current market overview
    > Reimbursement of key multiple sclerosis brands
    > Multiple sclerosis unmet needs
    > Unmet need 1: Efficacy for progressive subtypes
    > Unmet need 2: Therapies offering better clinical profiles
    > Unmet need 3: Drugs to halt or repair neuronal damage
    > Unmet need 4: Improving multiple sclerosis induced cognition dysfunction
    > Unmet need 5: Need for improved adherence
  • Current therapies
    > Clinical trial results of marketed therapies
    > Cross trial comparisons is not an ideal assessment
    > Tecfidera (dimethyl fumarate; Biogen) trends
    > Tecfidera becomes the latest FDA approved MS therapy
    > Tecfidera will become a first-line therapy and a major threat to Gilenya
    > Favourable label with no black box warnings and limited patient monitoring required
    > Discontinuation rates higher than existing therapies and may potentially get higher in a real world setting
    > Opportunity to expand draft label to include disability improvement
    > Treating warehoused patients will expand market
    > Practical Tecfidera pricing in-line with current first-line therapies
    > Tecfidera patent extended to 2028
    > Lemtrada (alemtuzumab; Genzyme/Sanofi) trends
    > Sanofi’s Lemtrada receives first worldwide approval
    > Lemtrada’s broad label is best case scenario for Sanofi
    > Lemtrada is one of the most effective marketed therapies
    > Safety concerns may hamper uptake
    > Sanofi will price Lemtrada in line with current treatments
    > Aubagio (teriflunomide; Sanofi/Genzyme) trends
    > Aubagio is approved by the FDA - drug becomes the second oral therapy to enter the market
    > Despite favourable tolerability the FDA have issued a black box warning on the prescription label
    > Surveyed neurologists are aware of Aubagio and intend to prescribe the drug
    > Interviewed neurologists believe Aubagio will find use as a monotherapy and combination therapy
    > Pricing at $45,000 places the drug cheaper than existing first-line therapies
    > Gilenya (fingolimod; Novartis) trends
    > Gilenya has first oral to market advantage
    > Gilenya raises bar for pipeline therapies entering the market
    > Deaths mar Gilenya’s side effect profile and positions drug as a second line
    > Vigilance program is cumbersome and likely to restrict access
    > Gilenya’s high price will restrict use
    > Clinical trials in progressive multiple sclerosis ongoing
    > Tysabri (natalizumab; Biogen) trends
    > Tysabri is the most effective approved multiple sclerosis therapy
    > PML fears positions drug as second or later line
    > JCV test will promote use and allay fears
    > Progressive multiple sclerosis trials ongoing for Tysabri
    > Copaxone (glatiramer acetate; Teva) trends
    > Copaxone is the leading selling multiple sclerosis therapy
    > Teva fights generic Copaxone applications
    > Interferon betas (Avonex, Betaseron, Rebif, Extavia) trends
    > Interferons are the mainstay of multiple sclerosis treatment
    > Needles have evolved to avoid injection site reactions
    > Biosimilar guidelines in place for interferons
    > Current treatment algorithm
  • Symptomatic Treatment
    > Multiple sclerosis symptoms
    > Symptomatic multiple sclerosis therapies
    > Ampyra/Fampyra (dalfampridine; Acorda Therapeutics/Biogen) trends
    > Controlled release formulation minimises risk of seizures
    > Ampyra only works in certain patient populations
    > High cost could restrict uptake
    > Sativex (nabiximols; GW Pharma/Almirall/Otsuka/Bayer/Novartis) trends
    > First cannabis -based drug enters Europe
    > Opinion leaders believe approval in US will follow European expansion
    > Partnerships will enable further market penetration
  • Pipeline therapies
    > Laquinimod (Teva) trends
    > Third laquinimod trial initiated concentrating on neuroprotective effect but doubts persist
    > Phase III efficacy data is disappointing and less than current therapies
    > Safety data and mechanism suits role as an add-on therapy
    > Daclizumab HYP (Biogen/Abbott) trends
    > Daclizumab complements Biogen’s portfolio with good safety and efficacy
    > Daclizumab positioning will be important for Biogen franchise
    > Ocrelizumab (Biogen/Roche) trends
    > Ocrelizumab represents the most advanced B-cell therapy
    > Ocrelizumab is highly effective in reducing relapses
    > Long-term safety needs to be investigated
    > Future treatment algorithm
    > More use of induction therapy in highly relapsing patients
    > Current first-line therapies will have a less prominent role in future treatment
    > Interferons and Copaxone can find a niche as combination therapies
    > Oral therapies will become the leading first- and second-line therapies
    > JCV test will drive earlier use of Tysabri
    > Potent but less safe therapies will remain last line
  • Future developments in multiple sclerosis
    > Constrained pricing environments will reduce market access
    > Clinically isolated syndrome will be considered early stage multiple sclerosis in the future
    > Trend for earlier diagnosis and treatment will produce better outcomes
    > Trend to more symptomatic therapies being developed
    > Eventual development of biomarkers will aid treatment
    > Better understanding of underlying multiple sclerosis etiology
    > Methods to assess treatment failure could be implemented in the future
    > More emphasis should be placed on long-term outcome measures
  • Appendix
    > KOL biographies
    > KOLs from North America:
    > KOLs from Europe

The MS KOL panel assembled for this Therapy Trends research is drawn from North America, Europe and Australia

  • Professor David Hafler, Chief and Chair of Neurology at Yale-New Haven Hospital and Yale School of Medicine, New Haven, Connecticut, US.
  • Professor Douglas Jeffery, MD, PhD, Associate Professor of Neurology, the Department of Neurology, The Multiple Sclerosis and Movement Disorders Centre at Advance Neurology at Cornerstone Health Care Winston-Salem, North Carolina, US
  • Professor Paul O’Connor, Professor, Division of Neurology, University of Toronto, Toronto, Canada
  • Professor Lawrence Steinman, Professor of Neurology and Neurological Sciences, Pediatrics, and Genetics, Stanford University School of Medicine, California, US
  • Professor and Medical Neurologist, MD, and expert in multiple sclerosis at the Ottawa Hospital Research Institute, Ottawa, Canada (requested anonymous).
  • Professor and Medical Neurologist, MD, and expert in multiple sclerosis at the Mount Sinai School of Medicine, New York, US (requested anonymous).
  • Dr Mike Bogglid, Staff Specialist Neurologist, Townsville Hospital, University of Queensland, Australia
  • Dr Patrick Vermersch, Department of Neurology, University of Lille North of France, Hôpital Roger Salengro, Lille, France
  • Dr Heinz Wiendl, Department of Neurology, Neuroimmunology and Neuro-Oncology, University of Muenster, Muenster, Germany
  • Dr Martin Wilson. Consultant Neurologist, Walton Centre for Neurology and Neurosurgery NHS Trust, Liverpool, UK
  • Professor and Medical Neurologist, MD, and expert in multiple sclerosis at Centre Neurologique et de Réadaptation Fonctionnelle, Fraiture-en-Condroz, Belgium (requested anonymous)
  • Professor and Medical Neurologist, MD, and expert in multiple sclerosis at Heinrich-Heine University, Düsseldorf, Germany (requested anonymous)

This report is continually updated in response to
market developments—stay in touch with the
latest developments and thinking and maximise
the value of this report

The world of pharma is ever changing and executives must always be up-to-date with the latest developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends updated offers real commercial advantage. Consider the benefits:

  • Content will be fully updated in response to market developments such as new product approvals or pivotal research results for 12 months from the date of purchase
  • Such updates are incorporated throughout the KOL reports ensuring the change is reflected in every aspect of the report
  • There is no limit and all relevant events will result in an update
  • You'll receive these updated directly, within days of each event's occurrence
  • All updates are included in the price.

Whatever happens in the market you’ll always be able
to assess the impact with FirstWord Therapy Trends.

Unrivalled Sources Ensure Complete Coverage

Our unique disease selection matrix pinpoints those disease sectors of the highest commercial potential, and draws information from multiple novel and expert sources, including

  • Exclusive views from leading global experts
  • Comprehensive consensus research
  • Live meeting dispatches and critical industry data
  • Data from over 125 medical conferences attended by FirstWord researchers each year
  • Online opinions from 535,000 vetted physicians
  • Over 2,000 peer-reviewed medical journals
  • Over 450 pharmaceutical news sources
Publication date:
 December 2013
$4,995 Single User License

Single user licenseAuthorizes use by the person placing the order only.

$9,990 Team License

Team licenseAuthorizes use by up to 10 employees of the Licensee who work within the same team or functional business unit.

$14,985 Global License

Global licenseAuthorizes use by any employee of the Licensee, including employees of the Licensee's affiliates.

Order Now

Key Benefits

  • Unmet needs analysis to identify opportunities and address the challenges facing disease management
  • Strategic mapping of future treatment algorithms based on KOL insight
  • Commercial and clinical analysis of pipeline therapies
  • In-depth, dynamic event impact assessments to evaluate current strategies and plans against new conditions
  • Align investment and resource planning to future trends
  • Know the story driving the trends

For users with responsibilities in

  • Business Development
  • New Product Planning
  • Market Research
  • Strategic brand planning
  • Forecasting and marketing professionals
  • Medical Affairs
  • Clinical Trials
  • Relationship Management

Informed Intelligence

  • The views from KOL panels comprising the foremost experts in the treatment and diagnosis of major medical conditions
  • Consensus ratings of therapeutic developments and events derived from a proprietary collaborative system involving 290,000 vetted physicians
  • Live dispatches from a correspondent network who attend 125+ medical conferences each year, feeding-in critical meeting intelligence
  • 2,000+ peer-reviewed medical journals
  • 450+ pharmaceutical news sources

Therapy Trends: Intelligence Two Ways

Therapy Trends Intelligence Reports: concise, focused, in-depth market intelligence research studies that examine current and late-stage pipeline drugs to determine future trends in the treatment and diagnosis of a specific medical condition and its impact on the commercial outlook

Therapy Trends Impact Assessments: dynamic analyst updates assess the impact of drug market events within days of a significant event happening